系统免疫炎症指数对根治性放疗Ⅲ期肺鳞癌患者长期生存的预测价值  

Predictive value of systemic immune inflammation index(SII)on long-term survival of patients with stage III squamous lung cancer treated with radical radiotherapy

作　　者：霍晶辰 王悦 李华 邱嵘[1] 苏景伟[1] 王卓凡 杨洁[1] HUO Jingchen;WANG Yue;LI Hua;QIU Rong;SU Jingwei;WANG Zhuofan;YANG Jie(Department of Radiotherapy,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050000,China;Department of Surgery,Hengshui Sixth People's Hospital)

机构地区：[1]河北医科大学第四医院放疗科,050000 [2]衡水市第六人民医院普外科

出　　处：《天津医药》2024年第6期634-638,共5页Tianjin Medical Journal

基　　金：河北省自然科学基金项目(H2023206301)。

摘　　要：目的探讨系统免疫炎症指数(SII)对接受根治性放疗的Ⅲ期肺鳞癌患者长期生存的预测价值。方法回顾性收集接受根治性放疗的Ⅲ期肺鳞癌患者的临床资料。计算患者放疗前1周内的SII及相关炎症指标,同时应用X-Tile软件确定最佳截断值。分析患者的生存情况以及SII对患者总生存(OS)及无进展生存(PFS)的影响。结果共纳入了453例患者,低SII组336例(<1277.3),高SII组117例(≥1277.3)。高SII组的中位OS和中位PFS均较低SII组缩短(OS:20.8个月vs.31.0个月,Log-rankχ2=18.015,P<0.01;PFS:13.0个月vs.21.0个月,Log-rankχ2=15.062,P<0.01)。多因素Cox回归分析显示,高SII是患者OS(HR=1.628,95%CI:1.294~2.047,P<0.001)和PFS(HR=1.559,95%CI:1.240~1.961,P<0.001)的独立危险因素,其他的影响因素包括较晚的TNM分期、放疗疗效欠佳,HALP评分下降。结论SII可作为接受根治性放疗Ⅲ期肺鳞癌患者长期生存的评价指标,SII升高提示预后较差。Objective To investigate the predictive value of systemic immune inflammation index(SII)scores in long-term survival of patients with stage III squamous lung cancer treated with radical radiotherapy.Methods Clinical data of stageⅢsquamous lung cancer patients who underwent radical radiotherapy at the Radiotherapy Department of the Fourth Hospital of Hebei Medical University from January 2010 to December 2018 were retrospectively analyzed.The peripheral hematological indexes one week before radiotherapy were collected and recorded.X-Tile software was applied to determine the best cut-off values for continuous variables.Kaplan-Meier method was used to analyze overall survival(OS)and progression-free survival(PFS).Results A total of 453 patients were included in this study.There were 336 patients in the low SII group(<1277.3),and other 117 patients were in the high SII group(≥1277.3).The median OS and median PFS in the high SII group were shorter than those in the low SII group(OS:20.8 months vs.31.0 months,Log-rankχ2=18.015,P<0.01;PFS:13.0 months vs.21.0 months,Log-rankχ2=15.062,P<0.01).Multivariate Cox regression analysis showed that high SII was associated with OS(HR=1.628,95%CI:1.294-2.047,P<0.001)and PFS(HR=1.559,95%CI:1.240-1.961,P<0.001).Other influencing factors included late TNM stage,poor radiotherapy efficacy and decreased HALP score.Conclusion SII can be used to evaluate the long-term survival of patients with stage III lung squamous cell carcinoma receiving radical radiotherapy,and the increase of SII indicates a poor prognosis.

关 键 词：肺肿瘤 癌 非小细胞肺 存活率 无进展生存期 Ⅲ期肺鳞癌 放疗 系统免疫炎症指数 

分 类 号：R734.2[医药卫生—肿瘤]